

Table S1. Comparisons of Observed Pharmacokinetic Parameters between *MDR1* GG and AG Genotypes within a Treatment in Patients from the PK PP Population (n=44)

Parameter	Treatment	GG vs. AG RGM (90% CI)	Fixed Effect <sup>[1]</sup>	
			Genotype	Period
<b>Observed Parameter</b>				
AUC <sub>0-24</sub> (hr*ng/mL)	LCPT	91.6 (76.0, 110.4)	0.4356	0.2045
	IR-Tac	98.1 (82.8, 116.3)	0.8537	0.7951
C <sub>max</sub> (ng/mL)	LCPT	94.4 (76.8, 116.0)	0.6400	0.1286
	IR-Tac	86.7 (69.9, 107.5)	0.2714	0.8989
C <sub>min</sub> (ng/mL)	LCPT	90.7 (74.4, 110.5)	0.4113	0.4681
	IR-Tac	99.9 (83.8, 119.0)	0.9892	0.8815

Abbreviations: AUC<sub>0-24</sub>=Area under the concentration-time curve from time 0 to 24 hours; CI=Confidence interval; C<sub>max</sub>= Maximum observed concentration, peak; C<sub>min</sub>= Minimum blood concentration observed over the 24-hour interval (0–24 hours); this parameter is also referenced as C<sub>24</sub> because the value is directly taken from the observed concentration data at the 24-hour nominal time point; PK=Pharmacokinetics; PP=Per protocol; RGM=Ratio of geometric mean; TDD=Total daily dose.

[1] P-value from mixed effects ANCOVA models that included fixed effects of genotype and period; analysis was performed on log-transformed data; averages from Period 2 (Day 14) and Period 3 (Day 21) were calculated for each patient prior to analysis.